SynBiotic

Overview
Price performance
Financials
Research
Thematics

SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.

Latest Insights

Consumer |
Outlook

09.05.23

SynBiotic — Building the platform

Consumer |
Update

09.08.22

SynBiotic — Management update – on track

Consumer |
Update

06.12.21

SynBiotic — Further acquisitions

Consumer |
QuickView

01.11.21

SynBiotic — Building a cannabis platform

Visit Website

Sector

Consumer

Equity Analyst

Russell Pointon

Director, Consumer

Key Management

Daniel Kruse

CEO

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	24.0	163.2	59.9
Relative	24.7	144.4	42.4
52 week high/low	€13.9/€2.9

Financials

SynBiotic’s management has created a platform that spans the value chain in the cannabis and cannabinoid space, from cultivation and labs to distribution. SynBiotic’s business creates and markets cannabis and cannabinoid products, which have both medical and consumer applications, with management constantly looking to add to its portfolio. We believe SynBiotic is well-placed to benefit from any relaxation in legislation around cannabis and cannabinoid products in Germany, as per the published government white paper (Eckpunktepapier), as it already operates across the cannabis value chain and has expertise in the field.

Research

Update

Consumer

09.08.22